| Autor: |
Mizukami, Takuro, Hamaji, Koki, Onuki, Risa, Yokomizo, Ayako, Nagashima, Yoshie, Takeda, Hiroyuki, Umemoto, Kumiko, Doi, Ayako, Arai, Hiroyuki, Hirakawa, Mami, Horie, Yoshiki, Izawa, Naoki, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu, Shibata, Michi, Tanaka, Tsuneaki, Mikami, Shinya, Nakajima, Takako Eguchi |
| Předmět: |
|
| Zdroj: |
Nutrition & Cancer; 2022, Vol. 74 Issue 2, p539-545, 7p, 3 Charts, 2 Graphs |
| Abstrakt: |
Limited information is available regarding the impact of body weight loss (BWL) in patients with advanced gastric cancer (AGC) who receive second-line chemotherapy. We retrospectively reviewed data for consecutive AGC patients who received second-line treatment with taxane-based chemotherapy at our institution between January 2014 and September 2018. We calculated variables, including percent BWL per month during chemotherapy (%BWL/m), and analyzed the correlations between BWL and other clinicopathological parameters with survival. Forty-four AGC patients were registered (median age, 67.5 years; females, n = 16 [36.3%]; severe ascites, n = 12 [27.3%]). The median overall survival was significantly shorter among patients with a %BWL/m of 1% or more, compared with patients with less weight loss (6.3 mo, vs. 12.3 mo, P = 0.038). The %BWL/m (≥1% vs. <1%) was significantly correlated with survival in a univariate analysis (HR = 2.11, P = 0.04), and the survival period was shorter for patients with severe ascites (HR = 1.92; 95% CI, 0.90–3.90) and if their %BWL/m was 1% or more (HR = 2.01; 95% CI, 0.98–4.10) in a multivariate analysis. In conclusion, BWL during second-line chemotherapy was associated with a poor prognosis among patients with AGC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
